Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transgenic Goat Antithrombin Gains EU Nod

This article was originally published in The Pink Sheet Daily

Executive Summary

GTC Biotherapeutics' recombinant human antithrombin ATryn was granted European Union marketing authorization roughly six months after receiving an initial negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use

You may also be interested in...



GTC Completes BLA For Recombinant Clot Buster Atryn

Phase II study in sepsis DIC indication is actively enrolling, GTC says.

GTC Completes BLA For Recombinant Clot Buster Atryn

Phase II study in sepsis DIC indication is actively enrolling, GTC says.

GTC Anticipates Reaching U.S. Market In 2009 With Human Antithrombin ATryn

Company tells “The Pink Sheet” DAILY it will seek indications for larger patient populations than initial target of hereditary antithrombin deficiency.

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel